Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) passed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $0.89 and traded as high as $0.9434. Brainstorm Cell Therapeutics shares last traded at $0.9434, with a volume of 2,160 shares.
Brainstorm Cell Therapeutics Trading Up 9.2%
The business’s 50-day simple moving average is $0.98 and its two-hundred day simple moving average is $0.89. The company has a market capitalization of $13.54 million, a PE ratio of -0.28 and a beta of 0.28.
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) last announced its earnings results on Friday, August 14th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.06). On average, analysts forecast that Brainstorm Cell Therapeutics Inc. will post -3.01 EPS for the current year.
Brainstorm Cell Therapeutics Company Profile
BrainStorm Cell Therapeutics Inc is a biotechnology company developing cell-based therapies for neurodegenerative diseases. The company’s lead platform, NurOwn, uses a patient’s own bone marrow-derived mesenchymal stem cells, which are processed to secrete neurotrophic factors and then administered back to the patient. BrainStorm has investigated NurOwn as a potential treatment for conditions involving neuronal damage and degeneration.
The company’s clinical development work has focused primarily on amyotrophic lateral sclerosis (ALS), as well as progressive multiple sclerosis and other neurodegenerative disorders.
Read More
- Five stocks we like better than Brainstorm Cell Therapeutics
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
